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        Introduction 
  SCFs are multisubunit ubiquitin ligases that catalyze protein de-
gradation by bringing substrates into proximity with ubiquitin-
conjugating enzymes (  Deshaies, 1999  ;   Willems et al., 2004  ). 
F-box proteins are the SCF components that bind to substrates, 
and this often requires substrate phosphorylation within motifs 
termed phosphodegrons. Fbw7 (also called hCdc4 or hSel10) is 
a member of a family of F-box proteins that bind to substrates 
via WD40 repeats (  Welcker and Clurman, 2008  ). The consen-
sus motif recognized by Fbw7 was fi  rst determined for its yeast 
orthologue, Cdc4, and is called a Cdc4 phosphodegron (CPD; 
  Nash et al., 2001  ). 
  Fbw7 degrades proteins with key roles in cell division, 
growth, and differentiation, including cyclin E, c-Myc, Notch, 
c-Jun, sterol regulatory element binding proteins (SREBPs), and 
PGC-1     (  Gupta-Rossi et al., 2001  ;   Koepp et al., 2001  ;     Moberg 
et al., 2001 ;  Oberg et al., 2001 ;  Strohmaier et al., 2001 ;  Nateri et al., 
2004  ;   Welcker et al., 2004b  ;   Yada et al., 2004  ;     Sundqvist et al., 
2005  ;   Wei et al., 2005  ;   O  ’  Neil et al., 2007  ;   Thompson et al., 2007 ; 
  Olson et al., 2008  ). Cyclin E is the most thoroughly studied 
substrate and contains two CPDs that are phosphorylated 
by glycogen synthase kinase 3     and autophosphorylated by 
CDK2 (  Koepp et al., 2001  ;   Strohmaier et al., 2001  ;   Welcker 
et al., 2003  ;   Ye et al., 2004  ). 
  Many Fbw7 substrates are protooncogenes that are acti-
vated when Fbw7 is disabled, and Fbw7 is an important tumor 
suppressor (  Akhoondi et al., 2007  ;   Welcker and Clurman, 
2008  ). Constitutive Fbw7 disruption in mice causes embryonic 
lethality, whereas conditional Fbw7 ablation in T cells induces 
lymphomas (  Tetzlaff et al., 2004  ;   Tsunematsu et al., 2004  ; 
  Onoyama et al., 2007  ). Fbw7 inactivation by homologous re-
combination in human Hct116 colon carcinoma cells causes ge-
netic instability associated with cyclin E activation ( Rajagopalan 
et al., 2004  ). 
  The Fbw7 gene encodes three protein isoforms (Fbw7   , 
Fbw7   ,  and  Fbw7   ) generated by alternative splicing of unique 
5     exons to 10 shared exons. Each isoform is expressed from 
a distinct promoter, thereby allowing differential isoform ex-
pression. Importantly, the 5     exons contain signals that direct 
the isoforms to distinct subcellular compartments (Fbw7     is 
nucleoplasmic, Fbw7     is cytoplasmic, and Fbw7     is nucleolar; 
  Welcker et al., 2004a  ). Although a few isoform-specifi  c func-
tions have been described (e.g., nucleolar regulation of c-Myc 
by Fbw7     and recruitment of Pin1 to cyclin E by Fbw7   ; 
  Welcker et al., 2004a  ;   van Drogen et al., 2006  ), these studies 
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However, because the three isoforms reside in distinct subcellular 
locations, their relative concentrations within these compartments 
are unknown. 
  A gene-targeting strategy to create 
isoform-speciﬁ  c Fbw7 knockouts 
  We used AAV gene-targeting vectors to homozygously disrupt 
each Fbw7 isoform in Hct116 cells (  Hirata et al., 2002  ). 
The targeting vectors inactivated the isoform-specifi  c exons by 
the insertion of a selectable marker fl  anked by LoxP sites. After 
Cre-mediated excision of the selectable marker, stop codons 
were left behind in all three reading frames (  Fig. 1 C  ). We also 
made a vector that simultaneously disrupts all three Fbw7 
isoforms by targeting exon 2 (termed Fbw7-null hereafter). 
The targeting effi  ciency of the various vectors ranged from 0.5 
to 10% of the neomycin-resistant clones analyzed (unpublished 
data). Homozygous-null cells were obtained by two successive 
rounds of targeting. Cre-adenovirus was used to remove the neo 
cassette after each recombination. Correctly targeted and re-
combined clones were confi  rmed by PCR, Southern blotting, 
and genomic sequencing (not depicted and Fig. S1, available 
at http://www.jcb.org/cgi/content/full/jcb.200802076/DC1). 
Multiple independent clones were obtained with each construct 
to eliminate phenotypes caused by clonal variation. 
    Fig. 1 D   shows that Fbw7     protein is readily detected in 
the wild-type, Fbw7    -, and Fbw7    -null cell lines but is absent 
from either Fbw7    -null or the Fbw7-null cells, confi  rming that 
have used overexpression approaches. In fact, little is known 
about the roles of the endogenous Fbw7 isoforms in regulating 
substrates. To clarify these issues, we used a gene-targeting ap-
proach using adeno-associated virus (AAV) vectors to create 
a series of homozygous isoform-specifi  c Fbw7-null mutations 
in human colon carcinoma cells. 
  Results and discussion 
  Fbw7     is the most highly expressed and 
stable Fbw7 isoform 
 We used isoform-specifi  c real-time PCR to quantitate endogenous 
Fbw7 mRNA in exponentially growing human cells. We exam-
ined two transformed cell lines (Hct116 and U2OS) and two pri-
mary cell types (foreskin fi  broblasts and CD34+ umbilical cord 
blood cells). In each case, Fbw7     was most highly expressed, and 
was between 8- and 50-fold more abundant than Fbw7     and  67- 
and 135-fold more abundant than Fbw7     ( Fig.  1 A ).  Transfection 
of equal amounts of Fbw7 expression plasmids results in much 
higher amounts of Fbw7     than either Fbw7     or Fbw7     (unpub-
lished data). We thus examined the stability of ectopic FLAG-
Fbw7 proteins because we can only detect the endogenous Fbw7   
protein ( Fig. 1 D ). Fbw7   was stable (t  1/2   >  6 h), whereas the other 
two isoforms were labile (t  1/2     <   1 h;   Fig. 1 B  ). The high amount of 
Fbw7     mRNA expression and its prolonged protein stability sug-
gested that it is the most abundant protein isoform, and this was 
confi  rmed in Western analyses of endogenous protein (  Fig. 1 D  ). 
  Figure 1.       Expression and targeted inacti-
vation of Fbw7 isoforms.   (A) Fbw7 isoform 
mRNA abundance in the indicated cell types. 
(B) 293A cells were cotransfected with vec-
tors encoding FLAG-tagged Fbw7 (0.3   μ  g 
Fbw7     and 3   μ  g each of Fbw7     and Fbw7    ) 
and treated with cycloheximide (CHX) as 
indicated. The three isoforms are indicated. 
(C) Schematic demonstrating locations of in-
serted stop codons for each knockout genotype 
(see text). (D) Lysates were prepared from con-
ﬂ   uent p150 plates of Hct116 clones of the 
in  dicated genotypes and immunoprecipitated 
with polyclonal anti-Fbw7 antibody followed 
by immunoblotting with monoclonal anti-Fbw7 
antibody. (E) Real-time PCR analysis of relative 
Fbw7 isoform mRNA expression in Hct116 
Fbw7 knockout cells. Results are expressed as 
relative to wild-type Hct116 cells. Error bars 
show standard deviation (three replicates).     915 ISOFORM-SPECIFIC FUNCTIONS OF FBW7   • Grim et al. 
Fbw7    -null cells but less so in the other cell lines. These 
fi  ndings are consistent with autoregulation, whereby c-Myc 
protein overexpression represses c-myc transcription (  Grandori 
et al., 2000  ), but other homeostatic mechanisms may also 
attenuate changes in c-Myc steady-state abundance after 
Fbw7 inactivation. 
  The Fbw7-null and Fbw7    -null cells contained high 
levels of SREBP relative to the other knockout genotypes 
( Fig. 2 D , left). This was most apparent when we used a pT426-
phosphospecifi  c antibody, which recognizes a phosphorylated 
and active form of SREBP1 (  Fig. 2 D  , right;   Sundqvist et al., 
2005 ).  Thus  Fbw7    accounts for the majority of Fbw7 activity 
toward both c-Myc and SREBP1 in Hct116 cells. We note, 
however, that like cyclin E, these proteins are predominantly 
nucleoplasmic. We also examined c-Jun and Notch in the 
knockout cell lines. We did not fi  nd any consequences of Fbw7 
deletion in c-Jun turnover in several contexts in the Hct116 
series (unpublished data), possibly refl  ecting redundant turn-
over pathways. Moreover, Notch activity was barely detect-
able in Hct116 cells, and we could not perform further analyses 
of this pathway. 
  Isoform-speciﬁ  c cyclin E regulation 
 Fbw7  specifi  cally degrades cyclin E that is autophosphorylated 
and catalytically active, and assays that detect cyclin E  –  associated 
kinase activity or cyclin E CPD phosphorylations (pT62, pT380, 
and pS384) are sensitive measures of cyclin E degradation by 
Fbw7. Cyclin E abundance and kinase activity were elevated in ex-
ponentially growing Fbw7-null and Fbw7    -null cells but normal 
in Fbw7    -null and Fbw7    -null cells (  Fig. 3 A  ). Because Fbw7 
the knockout strategy produced null mutations. We could not 
detect endogenous Fbw7     or  Fbw7    protein. We used real-
time PCR assays to quantitate the Fbw7 isoform mRNAs in 
each Fbw7 knockout genotype (  Fig. 1 E  ). Each of the isoform-
specifi  c targeted insertions led to reduced levels of their cognate 
mRNAs (but not the nontargeted isoform mRNAs), and this likely 
resulted from nonsense-mediated decay. This was most appar-
ent with Fbw7     (96% mRNA reduction) and Fbw7     (80% 
mRNA reduction). Inactivation of either Fbw7     or  Fbw7   
modestly increased Fbw7     mRNA  expression.  As  Fbw7    is  a 
known target of p53 (  Kimura et al., 2003  ), this may be because 
of the fact that p53 activity is mildly induced by Fbw7-loss 
(unpublished data). No similar compensatory increases in 
the expression of either Fbw7     or  Fbw7    were seen in any of 
the genotypes. 
  Isoform-speciﬁ  c regulation of 
Fbw7 substrates 
  We examined cyclin E, c-Myc, SREBP1, c-Jun, and Notch in 
the Fbw7 knockout cell series. Although c-Myc abundance 
was similar in all fi  ve genotypes, its turnover was greatly 
prolonged in the Fbw7-null and Fbw7    -null cells (  Fig. 2, A 
and B  ). We previously found that Fbw7     regulated the nucle-
olar pool of c-Myc in U2OS cells (  Welcker et al., 2004a  ); 
however, we could not detect nucleolar c-Myc staining in any 
of the Hct116 cell lines (unpublished data), possibly refl  ect-
ing cell type  –  specifi  c differences. We used real-time PCR to 
address the paradox that Fbw7    -loss delayed c-Myc turnover 
but did not elevate its steady-state abundance (  Fig. 2 C  ). We found 
that c-myc mRNA was reduced by     60% in Fbw7-null and 
  Figure 2.       c-Myc and SREBP1 regulation in Fbw7-null cells.   (A) Lysates from two independent sets of targeted Hct116 cells were immunoblotted for c-Myc 
or Grb2 (see   Fig. 3 A   for Grb2 panel). (B) Fbw7 knockout Hct116 cells were treated with cycloheximide as indicated, and lysates were immunoblotted for 
c-Myc. (C) Real-time PCR analysis of c-Myc mRNA in the indicated Hct116 cells. Results are expressed as relative to wild-type Hct116 cells. Error bars show 
standard deviation (three replicates). (D) Lysates from the indicated Hct116 cells were immunoprecipitated with anti-SREBP1 antibody and immunoblotted 
for either total SREBP1 (left) or pT426 SREBP1 (right).     JCB • VOLUME 181 • NUMBER 6 • 2008  916 
cyclin E half-life was greatly prolonged in the Fbw7-and 
Fbw7    -null cells but normal in the Fbw7    - and Fbw7   -null 
cells (  Fig. 3 B  ). Thus, Fbw7     accounts for most cyclin E degra-
dation by the Fbw7 pathway. We note, however, that complete 
Fbw7 loss leads to somewhat higher steady-state cyclin E abun-
dance than Fbw7     loss (  Fig. 3 A  ), but the basis of this differ-
ence remains unclear. 
deletions in mice reduce cyclin E mRNA expression ( Tetzlaff et al., 
2004 ;  Tsunematsu et al., 2004 ), we examined cyclin E mRNA 
in all fi  ve genotypes and did not observe any signifi  cant differ-
ences between the cell lines (Fig. S2, available at http://www
.jcb.org/cgi/content/full/jcb.200802076/DC1). We also measured 
cyclin E degradation rates in each Fbw7 knockout line by 
labeling cells after synchronization in S-phase and found that 
  Figure 3.       Isoform-speciﬁ  c cyclin E regulation by Fbw7.   (A) Lysates from two independent clones of each Hct116 genotype were analyzed for cyclin E 
abundance and kinase activity (Grb2, loading control). (B) Pulse-chase analysis of cyclin E in Hct116 knockout lines. Cells were labeled 1 h after release 
from aphidicolin arrest (see text). Quantitation of the phosphorimage is depicted in the graph, and the primary data for each isoform-speciﬁ  c cell line 
is shown. (C) HeLa cells and 293A cells were transfected with the indicated Fbw7 siRNAs (    ,     ,     , and CR) or control siRNAs (GFP and C). Cyclin E 
abundance, kinase activity, and T62 phosphorylation were measured 72 h after transfection. (D) 293A cells and HeLa cells were cotransfected with a 
FLAG-Fbw7     expression vector in combination with the indicated siRNAs (    -tubulin, loading control). (E) 293A cells were transfected with vectors expressing 
myc-tagged wild-type or P382I cyclin E. Lysates were immunoprecipitated with anti-Myc tag antibody (9E10), and cyclin E abundance, kinase activity, and 
T62 phosphorylation are shown.     917 ISOFORM-SPECIFIC FUNCTIONS OF FBW7   • Grim et al. 
  Cell cycle  –  dependent cyclin E regulation 
  Because cyclin E degradation is triggered by autophosphoryla-
tion, we had predicted that it would be most severely affected by 
Fbw7 loss in S phase, when cyclin E  –  CDK2 activity normally 
peaks. We thus compared cyclin E abundance in asynchronous 
cells, early S-phase cells, and prometaphase cells (  Fig. 4 A  ). 
Surprisingly, cyclin E abundance in S-phase cells was similar 
among all fi  ve Fbw7 genotypes, and the major difference attrib-
utable to Fbw7 deletion was found in prometaphase cells. Deletion 
of either Fbw7     or Fbw7     did not signifi  cantly alter cyclin E 
abundance in any cell cycle phase. 
  We next released S-phase  –  synchronized cells from arrest 
and found that cyclin E abundance rapidly declined in the paren-
tal Hct116 cells but was maintained at high levels in Fbw7-null and 
Fbw7    -null cells (  Fig. 4 B  ). This was most apparent when we 
examined the amount of T62- and T380-phosphorylated cyclin E, 
which are the central phosphorylation sites in the two cyclin E 
CPDs and specifi  cally accumulate when Fbw7 is inactivated. 
Cyclin E phosphorylated on T62 and T380 abruptly declined 
between 6 to 9 h after release in wild-type cells but remained 
stable in Fbw7-null and Fbw7    -null cells. Cell cycle kinetics 
was similar in all fi  ve genotypes (unpublished data). 
  The relative sensitivity of cyclin E to Fbw7 in different 
cell cycle phases could result from changes in either Fbw7 or 
cyclin E. However, Fbw7 protein expression did not vary when 
cells were arrested in aphidicolin or nocodazole (  Fig. 4 C  ) or 
after release from an S-phase arrest (  Fig. 4 D  ). Thus, changes in 
Fbw7 abundance are unlikely to account for cell cycle  –  specifi  c 
cyclin E degradation. 
  Because the synchronization experiments in   Fig. 4 (A  –  D)   
used pharmacologic S-phase inhibitors that can trigger check-
point responses that inhibit cyclin E  –  CDK2 autophosphoryla-
tion, we used siRNA to knockdown Fbw7 in HeLa cells (which 
are readily and synchronously released from nocodazole) and 
 Our  fi  ndings indicate that Fbw7     is largely responsible 
for cyclin E regulation in Hct116 cells, whereas the other iso-
forms are dispensable. However, a recent study found that 
both Fbw7     and Fbw7     are sequentially required for cyclin E 
degradation in 293A cells (  van Drogen et al., 2006  ). In this 
work, Fbw7     did not directly ubiquitinylate cyclin E but in-
stead promoted cyclin E proline 382 (P382) isomerization 
by Pin1, after which cyclin E was ubiquitinylated by Fbw7   . 
To address this discrepancy, we used siRNA to inhibit each 
Fbw7 isoform or all three isoforms together in two cell lines. 
We confi  rmed the fi  ndings of   van Drogen et al. (2006)   in that 
Fbw7     knockdown increased cyclin E abundance in 293A 
cells (  Fig. 3 C  , right). In contrast, Fbw7     knockdown did not 
alter cyclin E abundance in HeLa cells (  Fig. 3 C  , left). Fbw7    
knockdown was verifi  ed by using a FLAG-Fbw7     reporter 
( Fig.  3  D ). 
 Surprisingly,  unlike  the  Fbw7    or common region siRNAs, 
Fbw7     knockdown in 293A cells did not increase cyclin E 
kinase activity or cyclin E  –  phosphorylated species (  Fig. 3 C  ). 
Because Fbw7     was found to target cyclin E for degradation af-
ter cyclin E P382 isomerization, we considered the possibility 
that P382 isomerization inactivates cyclin E and that the cyclin E  –
  CDK2 that accumulates after Fbw7     knockdown in 293A cells 
is P382 isomerized, catalytically inactive, and stable. We thus 
tested a cyclin E P382I mutant that was found to be degraded by 
Fbw7     alone and presumably mimics P382 isomerization. This 
mutant was active and phosphorylated in 293A cells, suggest-
ing that P382 isomerization does not inactivate cyclin E  –  CDK2. 
Overall, our studies show that Fbw7     is not required for cyclin E 
degradation in the cell types and assays we have examined. 
However, both Fbw7     and Fbw7     may regulate cyclin E degra-
dation in other contexts (  van Drogen et al., 2006  ;   Sangfelt et al., 
2008  ) and more work is needed to fully understand the complex 
relationships between cyclin E and Fbw7. 
  Figure 4.       Cyclin E sensitivity to Fbw7 varies 
during the cell cycle.   (A) The indicated Hct116 
cells were treated with either aphidicolin (S), 
nocodazole (G2M), or DMSO (A) for 16 h, 
and lysates were analyzed by Western blot 
(    -tubulin, loading control). Cyclin E abundance is 
shown. In each case,   >  90% of the nocodazole-
arrested cells were in G2M and   >  70% of the 
aphidicolin-arrested cells were in S phase (not 
depicted). (B) The indicated Hct116 cell clones 
were arrested in S phase with a sequential thy-
midine/hydroxyurea block and released for 
the indicated time periods. The abundance 
of cyclin E, phosphorylated cyclin E spe-
cies, and Grb2 (loading control) are shown. 
(C) Hct116 cells were treated as in A and ly-
sates were examined for Fbw7 and cyclin E 
expression. Fbw7-null cell lysates serve as neg-
ative control. (D) Hct116 cells were arrested 
and released from aphidicolin and Fbw7 
abundance was determined.     JCB • VOLUME 181 • NUMBER 6 • 2008  918 
Hct116 cells, cyclin E expression, activity, and S384 phosphory-
lation (an autophosphorylation site that functions as a reporter 
of cyclin E kinase activity [  Geng et al., 2007  ]) all peaked in 
S phase and were lowest in G2/M cells, and this was not affected 
by p21 knockdown. However, cyclin E exhibited an inverse ac-
tivity pattern in Fbw7-null cells: S-phase cells contained the 
highest amount of cyclin E protein yet the lowest amounts of 
kinase activity and S384 phosphorylation. p21 knockdown did 
not affect either the timing or magnitude of cyclin E activation 
and/or phosphorylation, 
  We next examined the amount of pY15-CDK2 (which is 
inactive) that is bound to cyclin E in Fbw7-null Hct116 cells. 
The amount of CDK2 Y15 phosphorylation varied dramatically 
and was highest in S-phase cells, intermediate in asynchronous 
cells, and barely detectable in prometaphase cells (  Fig. 5 C  ). 
Thus, the amount of CDK inhibitory phosphorylation correlated 
closely with cyclin E – CDK2-specifi  c activity during the cell cycle. 
These fi  ndings are consistent with previous studies demonstrat-
ing loss of inhibitory CDK2 phosphorylation as cells enter 
mitosis (  Gu et al., 1992  ). 
  These data indicate that when cyclin E  –  CDK2-specifi  c 
activity is very high, the stoichiometry of cyclin E autophos-
phorylation is also high and that this likely determines the amount 
of cyclin E that can bind to Fbw7. To test this idea, we used 
transfected FLAG-tagged Fbw7     to pull down endogenous 
examined cyclin E as cells traversed through G1 and S phase 
without using S-phase inhibitors (  Fig. 5 A  ). Again, we found that 
the consequences of Fbw7 inactivation were minimal in S-phase 
cells (10  –  15 h after release) compared with prometaphase cells 
(0 time point). The cell cycle kinetics in wild-type and Fbw7-
null cells were similar, as demonstrated by the timing of cyclin A 
expression (  Fig. 5 A  ) and fl  ow cytometry (not depicted). 
  One striking observation in HeLa cells treated with Fbw7 
siRNA (and Fbw7-null Hct116 cells;   Fig. 5 B  ) was the very high 
specifi  c activity of cyclin E  –  CDK2 in prometaphase cells com-
pared with S-phase cells. That is, although S-phase cells contain 
more cyclin E protein than nocodazole-arrested cells, the cyclin E  –
  CDK2 immunoprecipitated from prometaphase cells is much 
more active. Because cyclin E degradation is triggered by auto-
phosphorylation, these differences in specifi  c activity could under-
lie the differential sensitivity of cyclin E to Fbw7 during the 
cell cycle. 
  CDK2 activity can be regulated by CDK inhibitors or by 
inhibitory phosphorylations on threonine 14 and tyrosine 15 
(Y15). We evaluated both of these pathways in wild-type and 
Fbw7-null cells. p21 is a major regulator of CDK2 activity in 
some cell types (e.g., fi  broblasts) and is degraded in prometa-
phase cells by the anaphase-promoting complex (  Amador 
et al., 2007  ). We used siRNA to determine if p21 was preventing 
cyclin E degradation in S-phase cells (  Fig. 5 B  ). In wild-type 
  Figure 5.       Cyclin E  –  CDK2 activity varies during the cell cycle  . (A) HeLa cells were transfected with either control or Fbw7-siRNA and then 48 h later were 
treated with nocodazole for 16 h. Mitotic cells were shaken off and replated for the indicated times. Cyclin E abundance and activity, as well as cyclin A 
abundance (a marker of cell cycle synchronization) are shown (*, background band). (B) Hct116 cells or Fbw7-null Hct116 cells were transfected with 
either control or p21Cip1-speciﬁ  c siRNAs and, after 48 h, treated with aphidicolin (Aph) or nocodazole (Noc). Cyclin E abundance, activity, and S384 
phosphorylation are shown. The efﬁ  cacy of p21 knockdown is shown. (C) Fbw7-null Hct116 cells were treated with aphidicolin or nocodazole and lysates 
were immunoprecipitated with anti  –  cyclin E antibody. The amount of CDK2 and Y15  –  phosphorylated CDK2 bound to cyclin E is shown. (D) Increased Fbw7 
binding of cyclin E obtained from mitotic Fbw7-null lysates. Compare the amount of cyclin E that coprecipitates with Fbw7 in lanes 4 and 5 (middle).     919 ISOFORM-SPECIFIC FUNCTIONS OF FBW7   • Grim et al. 
  Cell synchronization/ﬂ  ow cytometry 
  Cells were treated with 5   μ  g/ml aphidicolin (EMD), 2.5 mM thymidine 
(Sigma-Aldrich), 40 ng/ml nocodazole (Sigma-Aldrich), or 2 mM hydroxyurea 
for 16 h, and cell cycle analyses were performed using propidium iodide  –
  based ﬂ  ow cytometry as previously described (  Welcker et al., 2003  ). For re-
lease experiments, cells were washed three times with PBS and released into 
normal media. 
  Immunoprecipitations, Western blotting, kinase assays, and pulse chase 
  Cells were lysed in NP-40 or TENT buffer supplemented with protease and 
phosphatase inhibitors. Lysates were normalized and analyzed by Western 
blot, immunoprecipitation, or kinase assays as previously described (  Clurman 
et al., 1996  ). For pulse chase, cells were treated with aphidicolin for 16 h and 
than washed with normal media. After 1 h, cells were starved in media with-
out methionine, labeled for 40 min in 0.5 mCi/ml TranS 
35  -label (MP Biomedicals) 
and chased in normal media with 40 mg/liter methionine. 
  siRNA 
  Previously described Fbw7 isoform-speciﬁ  c and control siRNA oligos (  van 
Drogen et al., 2006  ) were obtained from Sigma-Aldrich and siRNA targeting 
p21 was obtained from Cell Signaling Technology. Dharmafect was used for 
siRNA transfections (Thermo Fisher Scientiﬁ  c). 
  AAV targeting vector construction, viral production, and transfection 
  Gene targeting, including viral production, puriﬁ  cation, and titering, vector 
cloning, Hct116 transfection, screening by PCR, Southern blot, and geno-
mic sequencing, and AdCre-mediated removal of the selectable marker 
was performed as previously described (  Russell and Hirata, 1998  ) or by 
standard techniques. Complete primer and targeting vector sequences are 
available upon request. A representative targeting strategy and screening 
are shown in Fig. S1. Adeno-Cre viral stock was a gift from J. Chamberlain 
(University of Washington, Seattle, WA). 
  Protein stability 
  293A cells transfected with plasmids encoding FLAG-tagged Fbw7    , 
Fbw7    , and Fbw7     (  Welcker et al., 2003, 2004a  ) were treated with 
100   μ  g/ml cycloheximide and lysates were immunoblotted with anti-FLAG 
antisera (Sigma-Aldrich). For endogenous c-Myc, 200   μ  g/ml cyclohexi-
mide-treated cells were harvested in TENT buffer and immunoblotted with 
N262 antisera. 
  Quantitative PCR assays 
  Fbw7 isoform-speciﬁ  c primer sets included a 5     isoform-speciﬁ  c primer 
and a shared exon 3     primer. Total RNA was isolated from U2OS, 
Hct116, or human foreskin ﬁ  broblast cells using the RNeasy kit (QIAGEN). 
Human cord blood cell RNA was provided by I. Bernstein (Fred Hutch-
inson Cancer Research Center, Seattle, WA). cDNA was synthesized 
with the StrataScript QPCR kit (Stratagene). Quantitative PCR was per-
formed using SYBR green quantitative PCR master mix (Invitrogen) and 
an ABI Prism 7700 (Applied Biosystems). Serial dilutions of plasmid 
DNA in total RNA were used as a standard curve for absolute quantita-
tion of isoform mRNA levels (expressed as the molar amount of mRNA/
1   μ  g of total RNA). Analysis of Fbw7 isoforms and of c-myc in Hct116 
knockout cells used similar methods. Relative expression (normalized 
to RPL13) was calculated according to the manufacturer  ’  s (Applied Bio-
systems) instructions. 
  Cyclin E  –  FLAG  –  Fbw7 binding assay 
  Fbw7-null Hct116 cells were treated with aphidicolin or nocodazole for 16 h 
and lysed with TENT buffer. Equal amounts of lysate were mixed with 100   μ  l 
FLAG-Fbw7     lysate (from CaPO  4  -transfected 293a cells) and 10   μ  l M2 
FLAG agarose (Sigma-Aldrich), rotated for 2 h, washed, and analyzed by 
Western blotting. 
  Online supplemental material 
  Fig. S1 shows a general strategy for AAV gene targeting in Hct116 cells. Fig. S2 
shows real-time PCR analyses of cyclin E mRNA. Fig. S3 shows production 
of rabbit polyclonal anti-Fbw7 antibodies. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200802076/DC1. 
  The authors thank S. Reed for providing 293A cells and for helpful discussions. 
  This work was supported by grants from the National Institutes of Health 
(B.E. Clurman and D.W. Russell), National Institutes of Health Career Development 
Awards (J.E. Grim and H. Hwang), the Burroughs Welcome Foundation 
(B.E. Clurman), the American Society of Hematology (J.E. Grim), and the Leukemia 
and Lymphoma Society (M. Welcker). 
cyclin E from Fbw7-null Hct116 cells that were synchronized 
in either S-phase or prometaphase (  Fig. 5 D  ). As predicted, the 
amount of cyclin E that bound to Fbw7 was greatly elevated in 
the prometaphase cells compared with S-phase cells, even though 
the abundance of cyclin E protein was similar (because the cells 
were Fbw7 null). 
  In conclusion, our results show the utility of AAV-mediated 
gene targeting to study complex loci and reveal that a single 
isoform of Fbw7 is responsible for most Fbw7 functions, at least 
toward the substrates that we could examine. Furthermore, 
Fbw7-null cells provide a useful tool to clarify regulation of cy-
clin E during cell cycle progression. To this end, we found large 
variations in cyclin E – CDK2-specifi  c activity and cyclin E auto-
phosphorylation during the cell cycle. In S phase, cyclin E  –
 CDK2-specifi  c activity and the amount of cyclin E that can bind 
to Fbw7 is low. In contrast, prometaphase cells contain highly 
active cyclin E  –  CDK2, which leads to increased cyclin E auto-
phosphorylation and Fbw7 binding. Thus, changes in cyclin E 
autophosphorylation play a critical role in regulating cyclin E 
periodicity during the cell cycle by determining the accessibil-
ity of cyclin E to Fbw7. Indeed, tumor cells with Fbw7 mutations 
exhibit loss of cyclin E periodicity (including mitotic cyclin E 
expression;   Ekholm-Reed et al., 2004  ). Interestingly, cyclin E is 
phosphorylated on both T62 and T380 in S phase (although it is 
not certain that both are on the same cyclin E molecule), and our 
recent studies indicate that these phosphorylated forms of 
cyclin E can only be degraded by Fbw7 dimers (  Welcker and 
Clurman, 2007  ). Thus, one possibility is that Fbw7 dimeriza-
tion is limited in S phase and that this restricts cyclin E turnover. 
However, our data clearly show that modifi  cations of cyclin E 
itself during the cell cycle regulate its interactions with Fbw7. 
In particular, autophosphorylation of S384 appears pivotal, as 
it stimulates rapid cyclin E degradation when CDK2-specifi  c 
activity is high. Our data also suggest that inhibitory CDK2 
phosphorylation limits S384 phosphorylation until mitosis, pro-
viding yet another level of regulation. Finally, because ectopic 
cyclin E activity causes genetic instability (  Spruck et al., 1999  ; 
  Minella et al., 2002  ) that may result from aberrant mitotic pro-
gression (  Rajagopalan et al., 2004  ;   Keck et al., 2007  ), robust 
cyclin E degradation in mitosis is likely to protect cells from 
these deleterious consequences of inappropriate cyclin E activity. 
  Materials and methods 
  Cell lines 
  Hct116 (J. Simon, Fred Hutchinson Cancer Research Center, Seattle, WA), 
human foreskin ﬁ  broblasts (W. Carter, Fred Hutchinson Cancer Research 
Center, Seattle, WA), 293A (S. Reed, The Scripps Research Institute, 
La Jolla, CA), HeLa (American Type Culture Collection), and U2OS cells 
(American Type Culture Collection) were maintained in DME with 10% FBS 
and penicillin/streptomycin. 
  Antibodies 
  Antibodies were obtained as follows: cyclin E, pT380 cyclin E, c-Myc, 
SREBP, cdk2,     -tubulin, and p21 (Santa Cruz Biotechnology, Inc.); Grb2 
(BD Biosciences); and anti-pY15Cdc2/CDK2 (EMD). Anti-pT62 cyclin E 
and -pS384 cyclin E (  Geng et al., 2003  ;   Ye et al., 2004  ), anti-p426 SREBP 
(  Sundqvist et al., 2005  ), and monoclonal anti-Fbw7 (  Nateri et al., 2004  ) 
have been previously described. Polyclonal anti-Fbw7 antisera were 
generated by ProSci Incorporated (Fig. S3, available at http://www.jcb
.org/cgi/content/full/jcb.200802076/DC1). JCB • VOLUME 181 • NUMBER 6 • 2008  920 
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